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Abstract
Background: Cell proliferation in all rapidly renewing mammalian tissues follows a circadian rhythm that is often disrupted
in advanced-stage tumors. Epidemiologic studies have revealed a clear link between disruption of circadian rhythms and
cancer development in humans. Mice lacking the circadian genes Period1 and 2 (Per)o rCryptochrome1 and 2 (Cry) are
deficient in cell cycle regulation and Per2 mutant mice are cancer-prone. However, it remains unclear how circadian rhythm
in cell proliferation is generated in vivo and why disruption of circadian rhythm may lead to tumorigenesis.
Methodology/Principal Findings: Mice lacking Per1 and 2, Cry1 and 2, or one copy of Bmal1, all show increased
spontaneous and radiation-induced tumor development. The neoplastic growth of Per-mutant somatic cells is not
controlled cell-autonomously but is dependent upon extracellular mitogenic signals. Among the circadian output pathways,
the rhythmic sympathetic signaling plays a key role in the central-peripheral timing mechanism that simultaneously
activates the cell cycle clock via AP1-controlled Myc induction and p53 via peripheral clock-controlled ATM activation. Jet-
lag promptly desynchronizes the central clock-SNS-peripheral clock axis, abolishes the peripheral clock-dependent ATM
activation, and activates myc oncogenic potential, leading to tumor development in the same organ systems in wild-type
and circadian gene-mutant mice.
Conclusions/Significance: Tumor suppression in vivo is a clock-controlled physiological function. The central circadian clock
paces extracellular mitogenic signals that drive peripheral clock-controlled expression of key cell cycle and tumor
suppressor genes to generate a circadian rhythm in cell proliferation. Frequent disruption of circadian rhythm is an
important tumor promoting factor.
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Introduction
Disruption of circadian rhythm increases spontaneous and
carcinogen-induced mammary tumors in rodents [1,2,3,4,5,6].
Epidemiological studies have revealed that human night-shift
workers show an increased risk of breast, colon, lung, endometrial
and prostate cancer, hepatocellular carcinoma and non-Hodg-
kin’s lymphoma [7,8,9,10,11,12]. Loss of circadian rhythm is also
associated with accelerated tumor growth in both rodents and
human cancer patients [13,14,15]. These findings raise the
question of how circadian dysfunction increases the risk of
cancers.
Circadian rhythms in mammals are generated by an endoge-
nous clock composed of a central clock located in the
hypothalamic suprachiasmatic nucleus (SCN) and subordinate
clocks in all peripheral tissues. The SCN clock responds to external
cues and drives peripheral clocks via circadian output pathways.
Both the central and peripheral clocks are operated by feedback
loops of circadian genes, including Bmal1, Clock, Period (Per1-3) and
Cryptochrome (Cry1 and 2). Bmal1 and Clock encode bHLH-PAS
transcription factors that heterodimerize and bind to E-boxes in
gene promoters to activate Per and Cry transcription, whereas Per
and Cry encode repressors of BMAL1/CLOCK. The alternating
activation and suppression of the BMAL1-driven positive loop and
the PER/CRY-controlled negative loop result in a circadian
oscillation of the molecular clock [16,17,18].
The molecular clock regulates clock-controlled genes (CCGs) to
control tissue/organ function. Most CCGs follow tissue-specific
expression patterns. Only a small group of CCGs, which include
key cell cycle regulators and tumor suppressors, are expressed in
all tissues studied. Such circadian control leads to the coupling of
cell proliferation with key tissue functions in vivo
[19,20,21,22,23,24]. Disruption of circadian rhythm in cell
proliferation is frequently associated with tumor development
and progression in mammals [4,5,12,25,26,27,28].
Both positive and negative loops of the molecular clock are
involved in cell cycle control. For example, BMAL1 suppresses
proto-oncogene c-myc but stimulates the tumor suppressor Wee1
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[30,31], and PER1 directly interacts with ATM in response to c-
radiation in vitro [32]. In mice, mutation in Per2 leads to
deregulation of DNA-damage response and increased neoplastic
growth [19,24,29]. In humans, deregulation or polymorphism of
Per1, Per2, Cry2, Npas2 and Clock is associated with acute
myelogenous leukemia, hepatocellular carcinoma, breast, lung,
endometrial and pancreatic cancers, and non-Hodgkin’s lympho-
ma [12,33,34,35,36,37,38,39,40,41].
However, peripheral clock-controlled gene expression is not
sufficient to generate and maintain the circadian rhythm of cell
proliferation because G1 cell cycle progression in normal somatic
cells is strictly controlled by extracellular mitogenic signals [42]. In
vivo, these signals include hormones, growth factors, cytokines and
neurotransmitters that follow cyclic changes over a 24 hour period
since they are either directly released from circadian output
pathways or encoded by CCGs in peripheral tissues [43,44,45].
We hypothesize that cell proliferation in vivo is paced by both
central and peripheral clocks. The central clock-controlled
mitogenic signals simultaneously actives the cell cycle and
peripheral clocks leading to a circadian coupling of cell cycle
and tumor suppressor gene expression. Disruption of circadian
rhythm promotes tumor development due to, at least in part, loss
of the homeostasis of cell cycle control.
To test our hypothesis, we studied the role of circadian
homeostasis of the sympathetic nervous system (SNS) in tumor
suppression. The central clock generates a robust circadian
rhythm in SNS signaling via direct and indirect targeting of the
presympathetic neurons located in the hypothalamic autonomic
paraventricular nucleus [43]. In vivo, the SNS controls all
peripheral tissues by releasing the hormones epinephrine and
norepinephrine that target adrenergic receptors (ADRs) on the cell
membrane [46]. Norepinephrine is directly released from
postganglionic sympathetic neurons, whereas epinephrine is
released from preganglionic sympathetic neuron-controlled chro-
maffin cells located in the adrenal medulla [46]. We have
previously reported that all circadian gene-mutant mice studied
show hyperplastic growth of osteoblasts in bone, and that b-
adrenergic receptor (ADRb) activation leads to Per and Ap1
induction in primary osteoblasts. In addition, AP1 directly
activates c-myc, whereas BMAL/CLOCK prevents myc over-
expression [29]. Since the induction of Per leads to peripheral
clock activation [47] and that the activation of c-myc initiates cell
proliferation [48], SNS signaling could be a circadian time cue for
both cell cycle and peripheral clocks. Therefore, SNS dysfunction
may disrupt the circadian homeostasis of cell cycle control in
peripheral tissues.
Here we report that all circadian gene-mutant mouse models
studied are cancer-prone and that hyperplastic growth of Per-
mutant somatic cells is dependent upon extracellular mitogens.
Rhythmic SNS signaling plays a key role in pacing cell
proliferation rate in peripheral tissues by simultaneously activating
Ap1-c-myc and ATM-p53 signaling. However, activation of Ap1 by
SNS signaling is independent of the peripheral clock while
activation of ATM is peripheral clock-dependent. Disruption of
circadian rhythm desynchronizes the central clock-SNS-peripheral
clock axis, suppresses peripheral clock function and abolishes
peripheral clock-dependent ATM activation, leading to myc
oncogenic activation and increased incidence of tumors in wild-
type mice. Our studies identify a previously unknown molecular
pathway that links disruption of circadian rhythm with oncogen-
esis and demonstrate that tumor suppression in vivo is a clock-
controlled physiological process but not a non-clock function of a
specific circadian gene.
Results
Tumor Suppression in vivo Is Not a Cell-autonomous
Function
We found that when kept in 24 hour alternating light-dark
conditions (24hr LD cycles), mice deficient in Bmal1 (Bmal1
+/2),
Cry1 and Cry2 (Cry1
2/2;Cry2
2/2), Per1 and Per2 (Per1
2/2;Per2
m/m)
or Per2 alone (Per2
2/2) were all cancer-prone. About 10–15% of
Bmal1
2/2 mice also showed hyperplasia of salivary glands in spite
of a significant reduction in the size of other major organ systems
due to aggressive aging [49]. Bmal1
+/2, Cry- and Per-mutant mice
all showed increased risk of ulcerative dermatitis and hyperplasia
in the salivary gland, preputial gland, liver and uterus as well as
spontaneous lymphoma, liver and ovarian tumor development,
although spontaneous tumors in Cry-mutants were mostly
identified after 50 weeks of age, later than that of Per1
2/2;
Per2
m/m and Per2
2/2 mice (Fig. 1a, Table 1, Fig. S1a and data not
shown).
A sublethal dose of c-Radiation induced premature aging on the
external appearance of all circadian gene-mutant mouse models
studied and further increased incidence of tumor and hyperplasia as
well as ulcerative dermatitis in Bmal1
+/2, Per-a n dCry-mutant mice
(Fig. 1b, Table 1 and Fig. S1b). About 8% of irradiated Bmal1
2/2
mice also developed lymphoma despite an average lifespan of 27
weeks due to a further accelerated rate of aging (Fig. 1c and Table 1).
Irradiated Bmal1
+/2 mice showed a similar rate of tumor
development as did irradiated Per2
2/2 mice (Fig. 1d–e and
Table 1). Since all circadian gene-mutant mouse models show
increased sensitivity to c-radiation, we conclude that the molecular
clock functions in tumor suppression in vivo.
We then examined the role of the central clock in tumor
suppression by studying the effects of jet-lag (an 8hr phase-
advance followed by an 8hr phase-delay in the onset of the light
period every 3 days) on tumor development in mice. We found
that jet-lag further increased and hastened tumor development
in wt, Cry-a n dPer-mutant mice and induced pancreatic, kidney
and intestinal tumors in mutant mice. However, jet-lag did not
significantly change the overall survival and tumor development
of irradiated Bmal1
2/2 mice that were deficient in responding to
circadian light cues in the central clock (Table 1, Fig. 2a, Fig.
S1c and data not shown) [50]. Jet-lag also significantly changed
tumor spectrum and induced osteosarcoma, liver and ovarian
tumors, hyperplasia of the salivary gland, liver and uterus as
well as severe seminal vesicle enlargement in wt mice (Table 1.
Fig. 2b–g, Fig. S1d–l and data not shown). In addition, although
when kept 24hr LD cycles, female circadian gene-mutant mice
showed an earlier onset and a higher tumor incidence compared
to male mutant mice, we did not found a significant gender
difference in total tumor incidence and the time of tumor onset
among irradiated and jet-lagged male and female mutant mice
(data not shown).
Sympathetic Signaling Is a Circadian Time Cue
We found that chronic jet-lag disrupted the circadian rhythm in
urine levels of creatinine and creatinine kinase and significantly
increased the risk of renal failure in mice (Table 1 and data not
shown). Mice that displayed fatal renal failure usually had only one
kidney left at the time of pathological examination which
completely lost filtration function due to severe hydronephrosis
leading to pressure atrophy and loss of the renal cortex (Fig. 3a–e).
Since renal failure has a strong correlation with sympathetic
dysfunction [51], this finding indicates that jet-lag disrupts the
homeostasis of multiple circadian output pathways including the
SNS. To test this hypothesis, we first studied urine catecholamine
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2/2;Per2
m/m mice. We found that in 24hr LD
cycles, both wt and Per1
2/2;Per2
m/m mice showed a two-peak
oscillation in norepinephrine and a one-peak oscillation in
epinephrine levels in urine (Fig. 3f–g). In constant darkness
(24hr DD cycles), the urinary catecholamine levels still oscillated
with a similar pattern as in 24hr LD cycles in wt mice, but were
significantly elevated and arrhythmic in Per1
2/2;Per2
m/m mice
(Fig. 3h–i). We conclude that one of the urine norepinephrine
peaks is generated by central clock-controlled postganglionic
sympathetic neuron activity, while the other is generated by
preganglionic sympathetic neuron-controlled chromaffin cells that
also rhythmically release epinephrine. Since the central clock in
Per1
2/2;Per2
m/m mice is driven by environmental light in LD
cycles but is not functional in DD cycles [52], these mice could
maintain a circadian rhythm of urinary catecholamine levels in
LD cycles but not in DD cycles.
We then studied whether the SNS rhythmically activates gene
expression in peripheral tissues. We found that among various
SNS targets studied, Ucp1 mRNA, which is expressed in brown
a d i p o s et i s s u eu n d e rt h ec o n t r o lo faCRE site in Ucp1 promoter
[53], could be used as a molecular marker to analyze the
activities of both central and peripheral clocks. In 24hr LD
cycles, Ucp1 mRNA showed a two-peak expression in wt BAT,
with the first peak appearing at ZT10 and the second at ZT22.
In Per1
2/2;Per2
m/m BAT, only the ZT22 peak was observed
( F i g .4 a – b ) .I n2 4 h rD Dc y c l e s ,Ucp1 mRNA still followed a two-
peak expression in wt BAT, but was arrhythmic and high in
Per1
2/2;Per2
m/m BAT (Fig. 4c–d). In wt mice, the activation of
CREB peaked between ZT10 and ZT18 (Fig. S2a–b). Loss of
function in Per1 and Per2 had no effect on CREB activation
induced by ADRb signaling (Fig. S2c), but abolished the
peripheral clock activity as shown by lacking a rhythmic
expression of Per2 and Bmal1 mRNAs in Per1
2/2;Per2
m/m BAT
(Fig. 4e–g). Thus, we conclude that the ZT10 peak of Ucp1
mRNA is generated by a collaborative activity of the central and
peripheral clocks, whereas, the ZT22 peak of Ucp1 mRNA is
exclusively controlled by the central clock.
We next examined the effect of jet-lag on Ucp1 mRNA
expression in wt mice on the second day after one cycle of jet-lag.
We found that although the ZT22 peak of Ucp1 mRNA was
found in both control and jet-lagged mice, the ZT10 peak of Ucp1
mRNA was absent in jet-lagged mice, which correlated with a
lack of rhythmic expression of Per2 and Bmal1 mRNAs in the
same BAT (Fig. 4h–i, Fig. S2d–e). We then studied Ucp1
expression in wt mice treated with chronic jet-lag for 10 months
and found that Ucp1 mRNA expression followed a similar pattern
in these mice compared to wt mice treated with only one cycle of
jet-lag (Fig. 4j–k). Together, our studies demonstrate that
although the central clock in mice always couples to external
light cues, acute jet-lag promptly disrupts the coordination of the
central and peripheral clocks, whereas chronic jet-lag abolishes
the peripheral clock function in the absence of circadian gene
mutations.
Sympathetic Signaling Is a Mitogenic Signal
To investigate whether SNS signaling stimulates cell cycle
progression, we treated wt and Per1
2/2;Per2
m/m calvarial osteoblasts
(preosteoblasts) with isoproterenol (iso), a synthetic agonist for
ADRb2a n db3 expressed on the preosteoblast cell membrane
[54,55]. We found that iso induced Ap1, c-myc and cyclin D1 mRNAs
as well as Cyclin D1 protein in both wt and Per1
2/2;Per2
m/m
preosteoblasts, but the level of c-myc and cyclin D1 induction was
significantly elevated in Per-mutant cells (Fig. 5a–c). The induction of
c-myc by iso was c-fos-dependent (Fig. 5d). Iso activated Per and c-fos in
preosteoblasts via ADRb3, or both ADRb2a n dA D R b3s i n c e
ADRb2
2/2 preosteoblasts showed an intact Per1 and c-fos induction
by iso (Fig. 5e). We then studied whether iso stimulates osteoblast
proliferation. We found that Per1
2/2;Per2
m/m osteoblasts showed a
higher G2 cell population compared to wt controls when grown in
mediacontaining 10% serum (Fig. 5f), which indicates that thesecells
had an accelerated rate of proliferation. However, under serum-
starved conditions, wt and Per1
2/2;Per2
m/m osteoblasts arrested
equallywell(Fig. 5g).Isoinduced cellcycle progression in both wt and
Per1
2/2;Per2
m/m preosteoblasts but iso-treated Per1
2/2;Per2
m/m
osteoblasts needed less time to progress from G1 to G2 phase
compared to wt controls (Fig. 5h). The accelerated proliferation of
Per1
2/2;Per2
m/m osteoblasts correlated with the over-induction of
c-myc and Cyclin D1 by iso in these cells (Fig. 5a–c). Thus,
hyperplastic growth of Per1
2/2;Per2
m/m osteoblasts is dependent on
extracellular mitogenic signals.
The SNS Activates ATM-p53 Signaling to Prevent Myc
Oncogenic Activation
Since p53 plays a key role in preventing Myc oncogenic activation
[48], we studied whether iso also induces p53 expression in
preosteoblasts. We found that p53 was induced by iso with kinetics
similar to AP1 transcription factors in wt osteoblasts. However, iso-
treated Per1
2/2;Per2
m/m osteoblasts showed AP1 overexpression in
the absence of p53 induction (Fig. 6a). The expression of p53 is
mainly controlled by its interaction with the E3 ubiquitin ligase
MDM2 in vivo [56,57]. Thus, we examined MDM2 expression in iso-
treated preosteoblasts. We found that MDM2 was suppressed by iso
with the same kinetics as p53 induction in wt osteoblasts, but
remained high in Per1
2/2;Per2
m/m osteoblasts (Fig. 6a). The MDM2-
p53 interaction is best studied in c-radiation response,whichactivates
protein kinase ATM that phosphorylates p53 at Ser18 (S18) and
MDM2 at Ser395 (S395) in mice. The phosphorylation at these two
sites blocks MDM2-p53 interaction, leading to MDM2 autoubiqui-
tination and p53 induction [58]. Since we used an anti-MDM2 2A10
antibody raised against a MDM2 C-terminal region containing the
S395 residue, the interaction of 2A10 with MDM2 could be blocked
by MDM2 S395 phosphorylation [58]. Thus, we studied MDM2 and
p53 expression in iso-treated preosteoblasts using an anti-p53 S18
antibody and an anti-MDM2 AB4 antibody that interacts with
MDM2 at the N-terminal region.Wefound that these two antibodies
detected a similar rate of p53 induction and MDM2 degradation in
wt osteoblasts as shown by the p53 PAb421 and MDM2 2A10
Figure 1. Circadian Gene-mutant Mice Are Cancer-prone. (a) Representative histological slides of cystic hyperplasia of the uterus,
spontaneous ovarian and liver tumors, and lymphoma in the livers of Cry- and Per-mutant mice. (b) All mutant mouse models studied show aging
phenotypes on their external appearance after exposure to a 4 Gy sublethal c-radiation at 6 weeks of age including hair graying, alopecia, ruffled fur,
skin lesions, cataracts and eye inflammation, hunchback postures, body weight changes, and sluggish activities. The ages of irradiated mice shown in
(b) are: Bmal1
2/2 mice at 3–6 months of age, Bmal1
+/2 mice at 6–8 months of age, Cry1
2/2;Cry2
2/2 mice at 3–6 months of age, Per2
2/2 mice at 6–8
months of age, Per1
2/2;Per2
m/m mice at 6–8 months of age, and wt littermates at 6–8 months of age. (c) Representative histological slides show
lymphoma in the chest cavity of a 20-week old and the salivary gland of a 36-week old irradiated Bmal1
2/2 mouse, and the active bone marrow in a
40 week-old irradiated Bmal1
2/2 mouse that also displayed aging phenotype on the external appearance. The Kaplan-Meier survival curves of (d)
Bmal1
+/2 and (e) Per2
2/2 mice (2IR: untreated, +IR: irradiated, p1: untreated wt vs. untreated mutant littermates, and p2: irradiated wt vs. irradiated
mutant littermates).
doi:10.1371/journal.pone.0010995.g001
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PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e10995antibodies but failed to detect p53 S18 induction and MDM2
decrease in Per1
2/2;Per2
m/m osteoblasts (Fig. 6b). We then studied
p53 induction in iso-treated wt and Atm
2/2 preosteoblasts. We found
that in wt osteoblasts, ATM was activated by iso, as shown by ATM
S1981 phosphorylation [59], in an iso dose-dependent manner and
that the duration and the levelsof ATMactivation correlated with the
level of p53 S18 phosphorylation and total p53 accumulation. In
contrast, Atm
2/2 osteoblasts that lacked p53 S18 phosphorylation
failed to show p53 induction by iso (Fig. 6c–d). Together, our findings
indicate that the SNS activates p53 via ATM in a peripheral clock-
dependent manner.
SNS-controlled p53 Signaling Plays a Key Role in Tumor
Suppression
We then studied p53 expression and S18 phosphorylation in
vivo. We found that the expression of total p53 and p53 S18
phosphorylation followed a coupled circadian rhythm over a 24hr
period and peaked around ZT10 in most wt thymuses studied. In
Per1
2/2;Per2
m/m thymuses, p53 S18 phosphorylation was almost
undetectable, and the total p53 level was significantly dampened
over a 24hr period (Fig. 7a). In Atm
2/2 thymuses, the circadian
rhythm of p53 expression and p53 S18 phosphorylation was
completely abolished (Fig. 7b). In addition, in 24hr LD cycles, the
circadian expression of p53 was coupled with c-Fos and c-Myc in
all wt mouse tissues studied including thymus, liver, kidney and
white adipose tissues (Fig. 7c and data not shown).
We next studied p53 and c-Myc expression in the thymus of jet-
lagged wt mice and found that one cycle of jet-lag was sufficient
enough to uncouple p53 and Myc signaling, inhibit p53, and
stimulate Myc expression (Fig.7d–f). To further study the role of
p53 in clock-controlled tumor suppression, we crossed p53
2/2
mice with Per2
2/2 mice that have deficient peripheral clocks and
overexpress c-myc [19]. We found a Per2 and p53 dose-dependent
reduction in survival time in mice due to increased tumor
development. Complete loss of Per2 function reduced the average
life span of p53
2/2 mice from 6 months to 4 months (Fig. 7g) [60].
Figure 2. Disruption of Circadian Rhythm Promotes Tumor Development in Wild-type Mice. (a) The Kaplan-Meier survival curves of wt,
Cry1
2/2;Cry2
2/2, Per1
2/2;Per2
m/m and Bmal1
2/2 mice (2IR: untreated, +IR: irradiated, +IR/Shift: irradiated and jet-lagged, p1: untreated wt vs.
untreated mutant mice, p2: untreated wt mice vs. irradiated mice, p3: untreated wt mice vs. irradiated/jet-lagged mice, and p4: untreated vs.
irradiated Bmal1
2/2 mice). Median survival times in weeks (95% CI) are 79.7 weeks (79.2–80.1) for untreated, 78.6 weeks (77.5–79.7) for irradiated and
67.9 weeks (63.3–72.5) for irradiated/jet-lagged wt mice, 76.9 weeks (73.9–80.0) for untreated, 69.3 weeks (64.4–74.2) for irradiated and 54.9 weeks
(47.8–62.0) for irradiated/jet-lagged Cry1
2/2;Cry2
2/2 mice, 74.8 weeks (71.8–77.8) for untreated, 67.1 weeks (62.5–71.7) for irradiated and 56.1 weeks
(51.0–61.2) for irradiated/jet-lagged Per1
2/2;Per2
m/m mice, and 35.5 weeks (30.73–40.1) for untreated, 27.3 weeks (23.3–31.4) for irradiated and 28.5
weeks (24.4–32.5) for irradiated/jet-lagged Bmal1
2/2 mice. Representative pictures of (b) lymphomas in the salivary glands of irradiated/jet-lagged
Bmal1
2/2, Bmal1
+/2, Cry1
2/2;Cry2
2/2, Per2
2/2, Per1
2/2;Per2
m/m and wt (Per1
+/+;Per2
+/+) mice, (c) hepatocellular carcinomas in irradiated/jet-lagged
Bmal1
+/2, Cry1
2/2;Cry2
2/2, Per1
2/2;Per2
m/m, Per2
2/2 and wt (Bmal1
+/+ and Per1
+/+;Per2
+/+) mice, (d) ovarian granulosa cell tumors in irradiated/jet-
lagged Cry1
2/2;Cry2
2/2, Per1
2/2;Per2
m/m, Per2
2/2 and wt (Cry1
+/+;Cry2
+/+) mice, (e) osteosarcoma growing out from the spine into the chest cavity of
an irradiated/jet-lagged wt (Per1
+/+;Per2
+/+) mouse and on the back of an irradiated/jet-lagged Per2
2/2 mouse, (f) severe cystic hyperplasia of the
uterus in irradiated/jet-lagged Cry1
2/2;Cry2
2/2, Per1
2/2;Per2
m/m and wt (Per1
+/+;Per2
+/+) mice, and (g) seminal vesicles from an untreated 60-week old
wt (Per1
+/+;Per2
+/+) mouse and age-matched irradiated/jet-lagged Cry1
2/2;Cry2
2/2 and Per1
2/2;Per2
m/m mice.
doi:10.1371/journal.pone.0010995.g002
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PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e10995Figure 3. Circadian Control of Sympathetic Signaling. (a–e) Jet-lag induces fatal kidney failure in mice. The arrows indicate (a) severe cystic
renal dysplasia with hydronephrosis of the remaining kidney (.20 times enlarged) in an irradiated and jet-lagged Per1
2/2;Per2
m/m mouse, (b) the
remaining failed kidney in an irradiated and jet-lagged Cry1
2/2;Cry2
2/2 mouse, (c) the remaining failed kidney in an irradiated and jet-lagged wt
mouse, (d) the failed kidney next to the other apparently normal kidney from an untreated Bmal1
2/2 mouse, and (e) the remaining failed kidney with
kidney stones accumulated inside in an irradiated and jet-lagged wt mouse (Bmal1
+/+). (f–i) Summaries of urinary norepinephrine and epinephrine
levels in wt and Per1
2/2;Per2
m/m mice in (f–g) 24hr LD (ZT) and (h–i) DD (CT) cycles detected from 3 to 6 independent experiments (ZT: Zeitgeber
Time, with light on at ZT0 and off at ZT12; CT: Circadian Time, with CT0 as the beginning of the subjective day and CT12 as the beginning of the
subjective night) (6SEM).
doi:10.1371/journal.pone.0010995.g003
Figure 4. Central Clock-controlled Sympathetic Signaling is a Key Central-peripheral Timing Mechanism. (a) Northern blot of Ucp1
mRNA expression in wt and Per1
2/2;Per2
m/m BAT in 24hr LD cycles. (b) A summary of three independent Northern blot analyses described in (a)
(6SEM). (c) Ucp1 mRNA expression in wt and Per1
2/2;Per2
m/m BAT in 24hr DD cycles. (d) A summary of three independent Northern blot analyses
described in (c)( 6SEM). (e) Per2 and Bmal1 expression in wt and Per1
2/2;Per2
m/m BAT in 24hr LD cycles. Summaries of (f) Per2 and (g) Bmal1 mRNA
expression in 24hr LD cycles from three independent experiments (6SEM). (h) Per2, Bmal1 and Ucp1 mRNA expression in BAT from untreated
(Control) wt mice and wt mice treated with one cycle of jet-lag (Shift). (i) A summary of three independent Northern blot analyses described in (h)
(6SEM). (j) Ucp1 mRNA expression in BAT from age-matched control wt mice and wt mice treated with 10 months of chronic jet-lag. (k) A summary of
Ucp1 mRNA expression from three independent Northern blot analyses described in (j).
doi:10.1371/journal.pone.0010995.g004
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e10995We then treated p53
2/2 mice with jet-lag and found that jet-
lagged p53
2/2 mice showed increased liver and salivary gland
hyperplasia, kidney failure, and accelerated tumor development
compared to untreated control p53
2/2 mice. Lymphoma and
osteosarcoma were identified among jet-lagged p53
2/2 mice, with
10% of tumors being osteosarcoma (Fig. 7h and data not shown).
Discussion
We have found that circadian gene-mutant mice share common
aging and cancer-prone phenotypes although these symptoms may
be more evident at different times during lifespan or under
different physiological conditions in different mouse models.
Disruption of circadian rhythm abolishes the peripheral clock
which induces a tumor spectrum in wt mice similar to that found
in circadian gene-mutant mice. These findings demonstrate that
tumor suppression in vivo is a clock-controlled physiological
function but not a non-clock function of a specific circadian gene.
Epidemiological studies have shown that disruption of circadian
rhythm increases the risk of breast, prostate, endometrial, ovarian,
lung, colon and pancreatic cancers, as well as non-Hodgkin’s
lymphoma, osteosarcoma and hepatocellular carcinoma in
humans [7,8,9,10,11,12,40,41,61,62,63,64]. The role of circadian
dysfunction in mammary tumor development in rodents has also
been well-documented [1,2,3,4,5]. Our studies show that chronic
jet-lag also increases the risk of ovarian, kidney, intestinal and
pancreatic cancers, osteosarcoma, lymphoma and hepatocellular
carcinoma in mice. Together, these studies suggest that the
mechanism of clock-controlled tumor suppression is conserved
during evolution.
Irradiatedandjet-laggedmalewild-typemiceshowrelativelylower
tumor incidences and later onset of tumors than their female
Figure 5. Hyperplastic Growth of Per-mutant Osteoblasts Is Extracellular Signal-dependent. (a). Northern blot analysis of Ap1, c-myc and
Cyclin D1 induction in 10 mM iso-treated wt and Per1
2/2;Per2
m/m preosteoblasts. (b) Western blot analysis of Cyclin D1 expression in 10 mM iso-
treated wt and Per1
2/2;Per2
m/m preosteoblasts. The level of b-Actin in each sample is detected as a loading control. (c) A summary of Cyclin D1
induction from three independent Western blot analyses described in (b)( 6SEM). (d) Northern blot analysis of c-myc induction by 10 mM iso in wt
and c-fos
2/2 preosteoblasts. (e) Northern blot analysis of Per1 and c-fos induction by 10 mM iso in wt and Adrb2
2/2 preosteoblasts. The ratios of G1, S,
and G2 phase cells of wt and Per1
2/2;Per2
m/m calvarial osteoblasts as determined by flow cytometry analysis under the normal growth condition (10%
serum in culture media) (f), the serum starved condition (0.2% serum in culture media) (g), and at 16 hours after treatment with 10 mM iso (h). Per1
2/
2;Per2
m/m osteoblasts show an increase in G2 phase in less than 16 hours after iso treatment, whereas wt osteoblasts only show an increase in S
phase but not in G2 phase at the same time. The numbers below each histogram summarizes three independent flow cytometry analyses (6SEM).
Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0010995.g005
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PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e10995littermates. However, we did not find a significant gender-dependent
difference in the time of tumor onset and total tumor incidence
among irradiated and jet-lagged circadian gene-mutant mice.
Although a larger sampling size may show a gender-dependent
tumor development in irradiated and jet-lagged mutant mice, our
studies indicate that gender-independent mechanisms are also
involved in clock-controlled tumor suppression. Recently, nonsexual
hormones leptin and growth hormones have been linked to the
development of colon and breast cancers as well as non-Hodgkin’s
lymphoma in humans [65,66,67]. A role for SNS dysfunction in the
development and/or progression of various human cancers has also
been reported, which include prostate, breast, pancreatic, colon and
ovarian cancers, glioma, neuroblastoma, osteosarcoma, hepatocellu-
lar carcinoma, cholangiocarcinoma and non-Hodgkin’s lymphoma
[68,69,70,71,72,73,74,75,76,77,78]. These findings in conjunction
with our own studies indicate that circadian dysfunction of
sympathetic activity could promote tumor development indepen-
dently and/or synergistically with sex hormones.
The direct and indirect neuronal control of SNS by the central
clock and the multi-synaptic control of peripheral tissues by the
SNS have been intensively studied [43,46]. Our studies demon-
strate for the first time that in vivo, the rhythmic SNS signaling is a
key central-peripheral timing mechanism that couples cell
proliferation and tumor suppression with mammalian daily
physiology. Such circadian control provides a gender-independent
mechanism for tumor suppression. The identification of Ucp1 as an
endogenous reporter for both central and peripheral clock
activities in our studies also provides a powerful tool for analyzing
and comprising the status of endogenous circadian homeostasis
which could not be evaluated by behavioral studies due to the light
masking effect on the central clock.
Previous studies have shown that Per-mutant mice are cancer-
prone, whereas Cry1
2/2;Cry2
2/2 mice are deficient in cell
proliferation in the first 72 hours of liver regeneration
[19,22,24,29]. A similar deficiency in liver regeneration has been
reported for mice lacking the nuclear receptor FXR which are also
prone for spontaneous hepatocellular carcinoma [79,80]. These
findings, along with our own studies, suggest that cell proliferation
is differentially controlled under different physiological conditions
in vivo. Using the central clock-SNS-peripheral clock axis as a
model system, we propose that the central clock-controlled SNS
signaling generates a coupled AP1, peripheral clock, and ATM
activation. The activation of AP1 leads to myc-induced cell cycle
progression, while the activation of the peripheral clock inhibits
myc overexpression and is required for ATM activity. ATM then
induces p53 to prevent Myc oncogenic signaling by blocking p53-
MDM2 interaction. Disruption of circadian rhythm desynchro-
nizes the central clock-SNS-peripheral clock axis which suppresses
peripheral clock and peripheral clock-dependent ATM-p53
signaling but has no effect on c-myc activation. Together, these
events lead to Myc oncogenic activation that promotes genomic
instability and tumor development (Fig. 7i). Our model suggests
that the circadian clock plays a dual role in cell cycle control and it
suppresses tumor development by controlling the homeostasis but
not the inhibition of cell proliferation.
Our finding of the sympathetic control of ATM-p53 signaling
indicates that the induction of p53 occurs as an integrated part of
mammalian daily physiology in vivo. This finding has important
therapeutic implications. Recent studies indicate that cancer
chronotherapy improves therapeutic index [81]. This may, at
least in part, be explained by the fact that chronotherapy is usually
applied during the sleeping phase when the endogenous p53 level
is high, allowing host tissues to better tolerate genotoxic insults that
induces p53 and p53-dependent apoptosis in somatic cells
expressing low levels of p53. We have previously reported that
wt thymocytes are less protected from radiation-induced apoptosis
if mice are irradiated at ZT2 or ZT18 when the endogenous p53
level is low compared to thymocytes irradiated at ZT10 when the
endogenous p53 level is high (Fig. 7a–c) [19]. Further study of
clock-controlled ATM-p53 signaling is important for the develop-
ment of novel strategies for cancer prevention and treatment.
Materials and Methods
Animal Maintenance
Animal experiments were approved by the Baylor College of
Medicine Institutional Animal Care and Use Committee.
Research was conducted in compliance with the Animal Welfare
Act Regulations and other Federal statutes with regard to animals
and experiments involving animals and adheres to the principles
Figure 6. Sympathetic Signaling Activates p53 via ATM. (a) Western blot of p53, MDM2, c-FOS and c-JUN in 10 mM iso-treated wt and Per1
2/2;
Per2
m/m osteoblasts using anti-p53 PAb421, MDM2-2A10, c-FOS and c-Jun antibodies. (b) Western blot of p53 and MDM2 in 10 mM iso-treated wt and
Per1
2/2;Per2
m/m osteoblasts using anti-p53-S18 and MDM2-AB4 antibodies. (c) Western blot analysis of ATM-S1981 and p53 in 10 mM iso-treated wt
and atm
2/2 osteoblasts using anti-ATM-S1981, p53-S18 and p53-PAb421 antibodies. (d) Western blot analysis of ATM and p53 in 100 mM iso-treated
wt and atm
2/2 osteoblasts.
doi:10.1371/journal.pone.0010995.g006
Clock and Tumor Suppression
PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e10995set forth in the Guide for Care and Use of Laboratory Animals,
National Research Council, 1996. Mice were generated by
heterozygous breeding of C57BL/6 inbred strains of Bmal1
+/2
[50], Cry1
+/2;Cry2
+/2 [82], Per1
+/2;Per2
+/m [52], Per2
+/2 [19],
Per2
+/2;p53
+/2 and p53
+/2 [60] mice, and 129/C57BL6 hybrid
strain of Atm
+/2 mice [83], and maintained under standard
pathogen-free conditions of 2–5 per cage at 21uC–23uC with a
humidity of 50%–70%, an air-flow rate of 15 exchanges/hr and in
24hr L/D cycles (light on at ZT0 and off at ZT12) if no specific
light/dark conditions were described in the text.
Survival Curve Studies
Similar numbers of male and female mice of each genotype were
used for all survival curve studies. Mice were monitored 2–3 times a
week following the five Morton and Griffiths aspects of animal
conditions as a guide. Terminally-ill mice showed multiple symptoms
including lack of food-intake, difficulty in standing, walking and
breathing, visible abnormal growth at localized body parts, dramatic
loss of body weight, ulcerated skin infections that did not respond to
antibiotic treatment, and bleeding from the mouth, vagina, and/or
anus, etc. These mice were sacrificed before death and all their vital
organ/tissues were inspected. The major organs and tumors were
isolated and processed for histological analysis. More than 95% of
terminally-ill mice identified were diagnosed with grave pathological
conditions including metastasizing tumors that had caused extensive
damage of affected tissues, severe hyperplasia of reproduction organs
or renal failure that would have caused death. The estimated time of
natural death for these mice was #1 or 2 days from the time of
euthanasia.
Mouse Tissue and Urine Sample Collection
For collecting mouse tissues and urine samples in DD cycles,
mice were maintained in standard LD cycles for two weeks and
then placed in 24hr DD cycles for two days before being
sacrificed for sample collection. For collecting mouse tissue
samples from jet-lagged mice, mice were placed in 24hr LD
cycles for two days after jet-lag prior to tissue isolation at
indicated ZT times.
Figure 7. Circadian Expression of p53 Suppresses Tumor Development. Western blots of p53 expression in (a) the wt and Per1
2/2;Per2
m/m
and (b) the wt and atm
2/2 thymuses over a 24hr LD cycle (The PAb421 antibody also detected immunoglobulin heavy chain (IGH) in total protein
extracts from the thymus, which run above p53 as a 64 kDa band). (c) Western blot of p53, c-Fos and c-Myc in thymuses of wt mice over a 24hr LD
cycle. (d) A representative Western blotting of p53 and c-Myc expression in the thymus of control wt mice and wt mice treated with one cycle of jet-
lag (shift). A summary of three independent Western blot analyses described in (d) for control (e) and jet-lagged (f) wt mice (6SEM). (g) The Kaplan-
Meier survival curves of mice with different copies of p53 and Per2 (p1: p53
+/+;Per2
2/2 vs. p53
2/2;Per2
2/2 littermates, p2: p53
+/+;Per2
2/2 vs. p53
+/2;
Per2
2/2 littermates, and p3: p53
2/2;Per2
+/+ vs. p53
2/2;Per2
2/2 littermates). Median survival times in weeks (95% CI) are 55.8 weeks (52.03–59.58) for
p53
+/+;Per2
2/2 mice, 44.4 weeks (38.8–50) for p53
+/2;Per2
2/2 mice, 28.9 weeks (25.3–32.56) for p53
2/2;Per2
+/+ mice, and 21 weeks (18.1–23.9) for
p53
2/2;Per2
2/2 mice. (h) The Kaplan-Meier survival curves of control and jet-lagged p53
2/2 mice. Median survival times in weeks (95% CI) are 27.5
weeks (23.3–31.6) for control and 17.6 weeks (14.1–21.1) for jet-lagged p53
2/2 mice. (i) A model for circadian control of tumor suppression.
doi:10.1371/journal.pone.0010995.g007
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Mice were shifted every 3 days from 6 weeks of age between a
24hr LD cycle of 6:00am to 6:00pm light/6:00pm to 6:00am dark
and a 24hr LD cycle of 10:00am to 10:00pm dark/10:00pm to
10:00am light.
c-Radiation
Mice were irradiated at 6 weeks of age at ZT10 with a single
dose of 4Gy (16.8 cGy/sec) sublethal c-radiation in a cesium-137
Gammacell.
Histological Analysis
Tissue and tumor samples were fixed in formalin. Paraffin
sections were prepared and stained with haematoxylin and eosin
following standard procedures. All tumor types were confirmed by
histological diagnosis.
RNA and Protein Analysis
Northern and Western blot analyses were performed following
the standard procedures as described previously [19]. RNA
expression was detected by Northern blot analysis and quantified
using a Molecular Dynamics Storm 860 PhosphorImager/
Fluorima. Protein expression detected by Western blot analysis
was quantified using the ImageJ program.
Antibodies
Anti-MDM2 2A10 (Calbiochem), PAb421 (Oncogene), anti-c-
Fos (Santa Cruz), anti-c-Jun (Santa Cruz), anti-CREB S133 (Santa
Cruz), anti-c-Myc (Santa Cruz), anti-ATM-S1981 (Calbiochem),
anti-p53-S18 (R&D Systems), anti-MDM2 AB4 (Calbiochem),
anti-MDM2-H122 (Santa Cruz) and anti-b-Actin (Sigma).
Cell Culture
Calvarial osteoblasts (preosteoblasts) were isolated, cultured,
and treated with iso (Sigma, final conc. 10mM or 100mM) as
described previously [29].
Flow Cytometry
Cells were fixed in 70% ethanol, incubated with PBS containing
50mg/ml propidium iodide, 0.2% Tween 20, and 1 mg/ml RNase
at 4uC overnight, and then analyzed by a Becton Dickinson
FACScan flow cytometer using CellQuest software (Becton
Dickinson) as described previously [19,29].
Urine Catecholamine Assays
Urine norepinephrine and epinephrine levels were measured
using the Catecholamine Research Biotrak Assay System (Amer-
sham) by TLC following manufacturer’s instructions [29].
Statistical Analysis
All survival curves were plotted using the Kaplan-Meier survival
analysis software. Other statistical analysis was assessed by
Student’s two-tailed t-test. Values were considered statistically
significant at p,0.05.
Supporting Information
Figure S1 Neoplastic Growth and Tumor Development in
Circadian Gene-mutant Mice. (a) Uteri from untreated 7-week old
wt (Cry1+/+;Cry2+/+), Cry12/2;Cry22/2, and Per12/
2;Per2m/m mice. (b) Uteri from an untreated 60-week old wt
(Per1+/+;Per2+/+) and age-matched irradiated/jet-lagged
Cry12/2;Cry22/2 and Per12/2;Per2m/m mice. (c) Repre-
sentative pictures of lymphomas developed in the chest cavities of
irradiated/jetlagged Bmal12/2, Bmal1+/2, Cry12/2;Cry22/
2, Per22/2 and Per12/2;Per2m/m and wt (Per1+/+;Per2+/+)
mice. Histological slides showing (d) over-distended seminal
vesicles filled with seminal fluid in an irradiated/jet-lagged
Per22/2 mouse, (e) ulcerative necrotizing dermatitis of an
irradiated Cry12/2;Cry22/2 male mouse, (f) osteosarcoma in
an irradiated/jet-lagged Cry12/2;Cry22/2 mouse, and lym-
phoma in (g) the salivary gland of an irradiated Per12/2;Per2m/
m mouse, (h) the lung and (i) skeleton muscle of irradiated Per22/
2 mice, and (j) the ovary, (k) kidney and (l) liver of irradiated/jet-
lagged wt mice.
Found at: doi:10.1371/journal.pone.0010995.s001 (4.18 MB TIF)
Figure S2 Sympathetic Control of Gene Expression. (a) Western
blot analysis of the activation of CREB in the thymus of wt mice
over a 24hr LD cycle using an anti-CREB S133 antibody. (b) A
summary of CREB activation detected from three independent
experiments as described in (a) (6SEM). (c) CREB is activated by
iso in both wt and Per12/2;Per2m/m osteoblasts. (d) A summary
of Bmal1 mRNA expression in BAT of untreated (Control) and
jet-lagged (Shift) wt mice from 3 independent experiments
(6SEM). (e) A summary of Per2 mRNA expression in BAT of
untreated (Control) and jet-lagged (Shift) wt mice from three
independent experiments (6SEM).
Found at: doi:10.1371/journal.pone.0010995.s002 (0.30 MB
TIF)
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